TITLE

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

AUTHOR(S)
SIMONIAN, NANCY A.; MCALLISTER, ARTHUR; LULL, JULIA; LIU, CLARENCE; BLUMHARDT, LANCE D.; ALAIN LI WAN PO
PUB. DATE
April 1999
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Apr1999, p553
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66699800

 

Related Articles

  • Evaluating treatment effect within a multivariate stochastic ordering framework: Nonparametric combination methodology applied to a study on multiple sclerosis. Brombin, Chiara; Di Serio, Clelia // Statistical Methods in Medical Research;Feb2016, Vol. 25 Issue 1, p366 

    Multiple sclerosis is an autoimmune complex disease that affects the central nervous system. It has a multitude of symptoms that are observed in different people in many different ways. At this time, there is no definite cure for multiple sclerosis. However, therapies that slow the progression...

  • Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. Wiendl, Heinz; Meuth, Sven // Drugs;Jun2015, Vol. 75 Issue 9, p947 

    In individuals with multiple sclerosis, physical and cognitive disability progression are clinical and pathophysiological hallmarks of the disease. Despite shortcomings, particularly in capturing cognitive deficits, the Expanded Disability Status Scale is the assessment of disability progression...

  • Assessment of motor function in Multiple Sclerosis patients treated with Methylprednisolone. van Eijkeren, Frank; Reijmers, Ruud; van Munster, Erik; Hilbink, Mirrian // Indian Journal of Physiotherapy & Occupational Therapy;Oct-Dec2011, Vol. 5 Issue 4, p115 

    The objective of the current study was to exhaustively assess whether Methylprednisolone produces changes in physical functioning in different populations of people with MS, by using a battery of established instruments. Therefore, various measurement instruments regarding functioning of the...

  • Multiple sclerosis drug approved.  // Executive Health's Good Health Report;Feb97, Vol. 33 Issue 5, p8 

    Focuses on the US Food and Drug Administration's approval of Copaxone for the treatment of relapsing-remitting multiple sclerosis (MS). Features of the drug; Results of clinical trials of the drug; Difference to previous classes of multiple sclerosis drugs.

  • In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan! � Yes. Miller, David H // Multiple Sclerosis Journal;Mar2012, Vol. 18 Issue 3, p264 

    The article discusses the debate about patient report versus magnetic resonance imaging (MRI) in assessing disease progression relapsing-remitting multiple sclerosis (MS) patients. It states that magnetic resonance imaging (MRI) should be used in assessing the disease progression in patients...

  • Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis. Murdoch, David; Lyseng-Williamson, Katherine A. // BioDrugs;2005, Vol. 19 Issue 5, p323 

    Subcutaneous recombinant interferon-β-1a (Rebif®) 22 or 44µg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. It has shown benefits on outcome measures related to relapses, progression of disability, and...

  • Merck reports encouraging data from Phase III multiple sclerosis trial.  // PharmaWatch: Biotechnology;Aug2009, Vol. 8 Issue 8, p8 

    The article reports on the positive results on the Phase III multiple sclerosis trial conducted by Merck Serono, a division of Merck KGaA, in the U.S. The post-hoc analyses of Merck on the two-year placebo-controlled Clarity Phase III trial using cladribine tablets has recorded significant...

  • Subcutaneous Recombinant Interferon-β-1a (Rebif®): A Review of its Use in Relapsing-Remitting Multiple Sclerosis. Murdoch, David; Lyseng-Williamson, Katherine A. // Drugs;2005, Vol. 65 Issue 9, p1295 

    Subcutaneous recombinant interferon-β-1a (Rebif®) 22 or 44µg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis (RRMS). It has shown benefits on outcome measures related to relapses, progression of disability and...

  • R&D UPDATE: Multiple Sclerosis.  // PharmaWatch: CNS;February 2003, Vol. 2 Issue 2, p5 

    Reports on developments relating to the treatment of multiple sclerosis. Reduction in the inflammatory brain lesions and relapses in patients with relapsing forms of multiple sclerosis by Antegren, a drug co-developed by Biogen and Elan; Start of Ilex Oncology's phase II trial comparing Campath...

  • Immunomodulation 2.  // Multiple Sclerosis (13524585);Nov2007, Vol. 13 Issue 9, pS164 

    The article presents abstracts on medical topics which include the side effects and clinical outcome of daclizumab open-label therapy in multiple sclerosis, treatment of rituximabin patients with primary progressive multiple sclerosis, and the safety and efficacy of rituximab in adults with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics